Retigabine

Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maxim...

Full description

Saved in:
Bibliographic Details
Published in:Neurotherapeutics 2007, Vol.4 (1), p.149-154
Main Authors: Porter, Roger J., Nohria, Virinder, Rundfeldt, Chris
Format: Article
Language:English
Subjects:
Animals
Anticonvulsants
Brain - drug effects
Carbamates
Clinical Trials as Topic
Epilepsy
Epilepsy - drug therapy
Humans
Medical research
partial-onset seizures
Phenylenediamines
potassium channels
Retigabine
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase I and II studies, with very promising results. The maximal tolerated dose for most patients is 1,200 mg/day. Adverse effects have been largely CNS-related and mild; most have occurred during the titration periods in the various studies. At present, retigabine is in two pivotal phase III studies.
ISSN:1933-7213
1878-7479
1878-7479
DOI:10.1016/j.nurt.2006.11.012